Ascorbyl Palmitate / Dose Cancer Research Results

AsP, Ascorbyl Palmitate: Click to Expand ⟱
Features:
Ascorbyl palmitate is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C. Ascorbyl palmitate is a highly bioavailable, fat-soluble form of ascorbic acid (vitamin C) and possesses all the properties of native water-soluble counterpart, that is vitamin C.

Ascorbyl Palmitate — Ascorbyl palmitate (AP; also called L-ascorbyl palmitate, vitamin C palmitate) is the 6-O-palmitate ester of L-ascorbic acid, used primarily as a lipid-phase antioxidant/preservative (food additive E304(i), INS 304(i)) and in topical/cosmetic formulations. It is an amphipathic, fat-soluble vitamin C derivative that localizes to lipid interfaces and can be enzymatically hydrolyzed to ascorbic acid + palmitate (extent and site depend on formulation and biology). In the Nestronics index (pid 35), AP is linked to limited cancer-pathway annotations largely derived from a small nanoformulation literature rather than broad clinical oncology deployment.

Primary mechanisms (ranked):

  1. Lipid-phase antioxidant activity (radical scavenging; inhibition of lipid peroxidation at membranes/oil–water interfaces)
  2. Membrane redox modulation with possible pro-oxidant behavior under specific conditions (secondary; model-/matrix-dependent)
  3. IL-6/STAT3 signaling suppression with downstream anti-proliferative and pro-apoptotic effects (preclinical; prominent in AP nanoformulations)
  4. Anti-angiogenic signaling effects reported in tumor models (e.g., VEGF/NO axis; preclinical)
  5. Anti-migration/invasion effects (e.g., MMP-related readouts; preclinical)

Bioavailability / PK relevance: As a fatty acid ester, AP partitions into dietary and biological lipids; oral exposure is formulation-dependent and it is generally believed to undergo esterase-mediated hydrolysis to ascorbic acid plus palmitate. Human oncology-relevant systemic PK for intact AP is not well standardized in the open literature; most “therapeutic” claims rely on delivery systems (e.g., solid lipid nanoparticles) rather than conventional oral supplement dosing.

In-vitro vs systemic exposure relevance: Many mechanistic cancer studies use micromolar-to-millimolar in-vitro concentrations and/or nano-enabled delivery that can exceed typical systemic levels achievable from food-additive exposure; translation hinges on formulation, local delivery, and tumor targeting rather than simple oral dosing.

Clinical evidence status: Predominantly preclinical (in vitro/in vivo) and largely formulation-driven (nano/SLN platforms). No established role as an anticancer drug in routine clinical oncology; clinical use is mainly as an antioxidant excipient/food additive.

Ascorbyl Palmitate — Mechanistic Pathway Matrix (Cancer Context)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation control ↓ lipid peroxidation (context-dependent) ↓ lipid peroxidation P Antioxidant stabilization of lipid phases Core identity is a lipid-phase antioxidant used to protect fats/oils and membranes; mechanistic centrality is redox buffering rather than direct oncogene targeting.
2 ROS balance ↔ (model-dependent; can be pro-oxidant at high concentration or in specific matrices) ↔ (model-dependent) P Redox modulation Some datasets (including food-matrix and additive evaluations) note condition-dependent pro-oxidant behavior; interpret as context- and co-antioxidant–dependent rather than a fixed direction.
3 IL-6 / STAT3 axis ↓ (preclinical; strongest in nanoformulations) Unknown / not established R Anti-proliferative signaling shift STAT3↓ and IL6↓; primary open literature support clusters around AP nanoformulations reporting STAT3 pathway inhibition with tumor growth suppression.
4 Apoptosis ↑ (preclinical; formulation-dependent) ↔ / safety generally favorable at permitted exposures R Programmed cell death induction Often downstream of stress + signaling changes (e.g., STAT3 suppression) in tumor models; not a validated clinical anticancer mechanism for standard oral exposure.
5 Cell cycle regulation ↓ proliferation / cell-cycle arrest (model-dependent) ↔ G Growth suppression Reported G2/M arrest appears in AP nanoparticle studies; treat as secondary to upstream stress/signaling.
6 Angiogenesis / NO signaling ↓ VEGF / ↓ NO (preclinical) ↔ (context-dependent) G Anti-angiogenic phenotype VEGF↓/NO↓/angioG↓; evidence is not broad across tumor types and appears tied to specific experimental systems.
7 Migration / invasion ↓ MMP-related invasion signals (preclinical) ↔ G Reduced metastatic traits MMP9↓ and TumMeta↓; mechanistic specificity remains limited outside a small formulation-driven literature.
8 NRF2 axis ↔ (not clearly established as a primary AP mechanism) ↔ G Secondary antioxidant-response tuning Unlike many electrophilic polyphenols, AP’s primary chemistry is radical scavenging in lipid phases; NRF2 involvement (if present) is typically indirect and context-driven.
9 Clinical Translation Constraint Formulation-driven exposure requirement Food-additive exposures are low — Limits on oncology leverage Regulatory acceptance is for antioxidant use (GMP/food additive contexts), but oncology-relevant effects mostly rely on nano/targeted delivery; intact-AP systemic PK and tumor delivery are the main bottlenecks.

TSF legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
Scientific Papers found: Click to Expand⟱
5387- AsP,  PacT,    Ascorbyl palmitate-incorporated paclitaxel-loaded composite nanoparticles for synergistic anti-tumoral therapy
- in-vivo, Melanoma, B16-F10
Dose↝, TumCG↓, TumCP↓, BioAv↓, BioAv↑, other↑, Apoptosis↑, Bax:Bcl2↑, EPR↑, toxicity↝,
5386- docx,  AsP,    Co-delivery of docetaxel and palmitoyl ascorbate by liposome for enhanced synergistic antitumor efficacy
- vitro+vivo, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, Pca, PC3
Dose↝, ROS↑, eff↑, eff↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Bax:Bcl2↑, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Migration ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature ⓘ

EPR↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↑, 1,   Dose↝, 2,   eff↑, 2,  

Functional Outcomes ⓘ

toxicity↝, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: Dose, Dosage
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:35  Target#:1114  State#:%  Dir#:4
  wNotes=0  sortOrder:rid,rpid

 

Home Page